Sabrina Cuddy • January 26, 2024
February is Heart Month

Here are some HCM basics that everyone should know:

  • On average, we live as long as anyone else when we properly care for our HCM. 
  • We are more likely to get good care at a high-volume center – an HCMA-Recognized  Center of Excellence. The American College of Cardiologists and the American Heart Association guidelines for HCM agree about high-volume centers.
  • Most people have a few symptoms that are easily managed with medications. 
  • If you are a member of the HCMA Facebook Group, remember that those of us who seek support from the group often have more problems related to HCM. If you are newly diagnosed, you may be alarmed by what some are going through. Just know that your HCM may not be as dire as some accounts you read online. 
  • HCM is characterized by a thickening of the heart muscle (hypertrophy means “to thicken”). Even with minimal thickening, though, we can have symptoms due to heart muscle stiffness and other factors caused by myocardial disarray , which means the heart muscle cells aren’t lined up normally.  

Some HCM statistics

About 50% of adults with HCM present with symptoms. You can be diagnosed with HCM at any age. It’s common to be diagnosed during the teenage years, but the average age of diagnosis in the HCMA database is 39 years.  https://4hcm.org/hcm-development/  

70% of those with diagnosed HCM are obstructed (called HOCM); for more info, please see the  obstruction  page on our website.

25% of people with HCM will experience  atrial fibrillation , a serious arrhythmia. 

25% of people with HCM would benefit from ICD therapy to protect them from sudden cardiac arrest (SCA). Risk stratification for SCA can help you and your doctors decide if you need an ICD and what kind is best for you.  Traditional Transvenous ICD  –  Subcutaneous ICD Fewer than 5% of those with HCM will eventually need a  heart transplant.

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts